TCI GENE Inc. (TPEX:6879)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
37.00
-0.20 (-0.54%)
Apr 29, 2026, 11:36 AM CST
-20.26%
Market Cap 1.02B
Revenue (ttm) 273.61M
Net Income (ttm) 40.57M
Shares Out 26.46M
EPS (ttm) 1.52
PE Ratio 25.26
Forward PE n/a
Dividend 2.00 (5.38%)
Ex-Dividend Date Sep 5, 2025
Volume 11,101
Average Volume 14,402
Open 37.20
Previous Close 37.20
Day's Range 35.85 - 37.20
52-Week Range 32.45 - 47.35
Beta 0.22
RSI 57.46
Earnings Date May 13, 2026

About TCI GENE

TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-der... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6879
Full Company Profile

Financial Performance

In 2025, TCI GENE's revenue was 273.61 million, a decrease of -21.27% compared to the previous year's 347.54 million. Earnings were 40.57 million, a decrease of -27.96%.

Financial Statements

News

There is no news available yet.